PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 11717494

Conditional optimization: a new formalism for protein structure refinement.

S H Scheres·P Gros
View original source ↗Export metadata ↓

Abstract

Conditional optimization allows unlabelled loose-atom refinement to be combined with extensive application of geometrical restraints. It offers an N-particle solution for the assignment of topology to loose atoms, with weighted gradients applied to all possibilities. For a simplified test structure consisting of a polyalanine four-helical bundle, this method shows a large radius of convergence using calculated diffraction data to at least 3.5 A resolution. It is shown that with a new multiple-model protocol to estimate sigma(A) values, this structure can be successfully optimized against 2.0 A resolution diffraction data starting from a random atom distribution. Conditional optimization has potentials for map improvement and automated model building at low or medium resolution limits. Future experiments will have to be performed to explore the possibilities of this method for ab initio phasing of real protein diffraction data.

Explore related subjects

CrystallizationCrystallography, X-RayModels, ChemicalModels, MolecularPeptidesProtein ConformationJournal ArticleResearch Support, Non-U.S. Gov't

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

S H Scheres, P Gros. 2001-11-21. Conditional optimization: a new formalism for protein structure refinement.. https://doi.org/10.1107/s0907444901015414

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2003

High resolution X-ray structure of potent anti-HIV pokeweed antiviral protein-III.

Pokeweed antiviral protein III (PAP-III), a naturally occurring protein isolated from late summer leaves of the pokeweed plant (Phytolacca americana), has potent anti-HIV activity by an as yet undetermined molecular mechanism. PAP-III belongs to a family of ribosome-inactivating proteins that catalytically deadenylate ribosomal and viral RNA. The chemical modification of PAP-III by reductive methylation of its lysine residues significantly improved the crystal quality for X-ray diffraction studies. Trigonal crystals of the modified PAP-III, with unit cell parameters a=b=80.47A, c=76.21A, were obtained using 30% PEG400 as the precipitant. These crystals contained one enzyme molecule per asymmetric unit and diffracted up to 1.5A, when exposed to a synchrotron source. Here we report the X-ray crystal structure of PAP-III at 1.6A resolution, which was solved by molecular replacement using the homology model of PAP-III as a search model. The fold typical of other ribosome-inactivating proteins is conserved, despite several differences on the surface and in the loop regions. Residues Tyr(69), Tyr(117), Glu(172), and Arg(175) are expected to define the active site of PAP-III. Molecular modeling studies of the interactions of PAP-III and PAP-I with a single-stranded RNA heptamer predicted a more potent anti-HIV activity for PAP-III due to its unique surface topology and more favorable charge distribution in its 20A-long RNA binding active center cleft. In accordance with the predictions of the modeling studies, PAP-III was more potent than PAP-I in depurinating HIV-1 RNA.

Crystallization↗
PubMed2003

Characterization of piroxicam crystal modifications.

Piroxicam polymorphism was extensively studied in the past. The objective of the present work was to evaluate polymorphism of piroxicam once again and to characterize the obtained crystal forms. Three polymorphic forms and one monohydrate form were obtained by crystallization from saturated solutions in various solvents. Polarity of solvents and crystallization rate defined by temperature of crystallization were found to be critical parameters in determining the polymorphic form. A new polymorphic form designated as form III was obtained by forced crystallization using dry ice. Only form I with the highest melting point was found to be stable under mechanical and thermal stress. Differences in IR spectra were attributed mainly to the differences in number and positions of H-bonds in the piroxicam crystal forms. Slow crystallization of piroxicam from absolute ethanol solution resulted in a mixture of form II and monohydrate. Crystal structure analysis proved that form II represents form alpha(2) already proposed in the literature. Differences in dissolution rates among crystal forms of piroxicam were attributed to differences in their wettability, where highest wettability was obtained for monohydrate and the lowest for form III.

Crystallization↗